MD Anderson president to retire after nine years, interim successor named

retirement plan

Dr. Peter WT Pisters and Dr. Jeffrey E. Lee. Photos via mdanderson.org

An era is ending at The University of Texas MD Anderson Cancer Center.

On Aug. 26, Dr. Peter WT Pisters announced his plans to retire from his role as president of the comprehensive cancer center. He will work on a smooth transition of leadership with interim president Dr. Jeffrey E. Lee throughout September.

“I first arrived at UT MD Anderson 32 years ago with a passion for doing everything I could to advance our mission to end cancer. Serving as the only faculty member to become president, and now marking nine years in the role, I can say with great pride and gratitude that there is no better place than UT MD Anderson to turn hope into healing for patients and families everywhere,” Pisters said in a news release. “With a timeless strategy, a strong leadership team, unprecedented levels of financial health, and a priceless culture anchored in our deeply held Core Values, now is the right time for me to transition to other opportunities. UT MD Anderson has never been stronger, and its future has never been brighter.”

Pisters assumed the presidency in 2017 and helped launch some of the most cutting-edge new clinics in MD Anderson history. One of those was the James P. Allison Institute, named for the Nobel Laureate scientist who discovered a way to suppress immune response on tumors so that immune cells would attack cancer cells instead. As head of his titular clinic, Allison pioneered several new immunotherapies against cancer.

Pisters also oversaw the creation of the Institute for Data Science in Oncology in 2024, an innovative consortium of scientists dedicated to enhancing single-cell imaging to improve precision in cancer treatments. The institute also brought together teams to use data-driven analytics regarding safety, quality and access.

The UT System Board of Regents praised the leadership and work of Pisters in a statement, wishing him well in the next phase of his career.

“The Board of Regents and I are profoundly grateful to Dr. Pisters for his exceptional presidency over the past nine years and for thoughtfully concluding his service when UT MD Anderson is thriving at its best position of peak performance, strength and impact. We wish him our very best with his retirement and in his next chapter,” Kevin P. Eltife, chairman of the UT System Board of Regents, added in the release.

From Your Site Articles
This week's roundup of Houston innovators includes Chris George of Octopus EV, James Allison of MD Anderson, and Paul Wotton of RBL LLC. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a biotech leader, a Nobel laureate, and EV innovator.

Chris George, United States co-lead at Octopus Electric Vehicles

Chris George, United States co-lead at Octopus Electric Vehicles, joins the Houston Innovators Podcast. Photo courtesy of Octopus

Switching from a gas-powered car to an electric one can be a big change, but a Houston-based company has made things a lot easier for its customers.

Octopus Electric Vehicles US, a spinout of United Kingdom-based retail energy provider Octopus Energy, matches its users with their perfect EV lease and sets them up with smart electricity technology for at-home charging.

"We do a couple of really unique things that are not only first of its kind but really innovative," Octopus EV's US Co-Lead Chris George says on the Houston Innovators Podcast, pointing out specifically Octopus Energy's Intelligent Octopus, a smart feature for customers that automates energy usage to lower cost.

"We launched an Intelligent Octopus for EVs service. Instead of operating in a very narrow window — overnight — it operates dynamically," he continues. Read more.

James P. Allison, director of the James P. Allison Institute

MD Anderson's lab led by Nobel laureate James Allison has secured a $5 million donation. Photo courtesy of MD Anderson Cancer Center

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center scored a $5 million gift at its second annual symposium.

On behalf of Mayor John Whitmire, Oct. 10, 2024 was named “James P. Allison Institute Day,” and it was also the day that the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park greeted 900 attendees for the scientific symposium, entitled “Immunotherapy in Space and Time: The Tumor Microenvironment.”

“Spatial biology is a rapidly expanding field that offers tremendous new insights into immunobiology that were not possible just a few short years ago. Understanding how immune cells interact with their neighbors and with tumor cells in space and time will enable us to bring forward new strategies to improve immunotherapy outcomes,” says James P. Allison. “We are proud to host this annual symposium to advance the field, and we are extremely grateful for the support of the Wintermann Foundation to make new breakthroughs possible.” Read more.

Paul Wotton, managing partner of RBL LLC

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is Rice University's new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems." Continue reading.

From advice to observations, these five quotes overheard at SXSW proves Houston had some great spokespeople at the 2019 SXSW Interactive festival. Photos courtesy

Overheard: 5 powerful quotes from Houstonians speaking at SXSW

Eavesdropping in Austin

Houston had no shortage of representatives at the 2019 SXSW Interactive festival, which took place March 8 to 12 in Austin. Several sat on panels, lead mixers, or even starred in a movie for the film track of the conference.

I had the pleasure of sitting in on a great deal of these events featuring the best and the brightest of Houston's innovation stars, but I realize most did not. To catch you up and rid you of your fear of missing out, check out these five overheard quotes from the fest.

"I think it's so important to find your focus and know what to say no to, because you can't do it all. Elizabeth [Gore] and I have a monthly 'meeting of no' where we literally check off things off our plate that we need to stop doing because we just don't have enough time. It's probably one of our most valuable hours."

— Carolyn Rodz, co-founded Alice with Elizabeth Gore. Alice co-hosted a series of panels at the Bumble Hive. She was asked, during the investment-focused panel, about focusing on B-to-B vs. B-to-C as a startup. Alice and Bumble just recently announced a partnership.

"We're trying to awaken the sleeping giant — a really huge city with lots of money, trying to infiltrate and activate huge family offices and rally people behind the goal of building a vibrant startup community. We've got a long way to go in terms of attracting VC talent — we're still behind Austin and Dallas."

— Lawson Gow, founder and CEO of The Cannon, at the Austinpreneur podcast recording of "The Texas Startup Manifesto" episode. He was asked about what he's been trying to accomplish at The Cannon. Gow is the son of InnovationMap's parent company's CEO.

"We've got all the basic tools, and we know what the main issues are. There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

— James Allison, chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center. At his panel, "Making the Fight Against Cancer Even More Personal," he was asked about the current status of immunotherapy research.

“Have very specific questions. I hate the ‘can I pick your brain’ request. If you want advice on something, ask me that specifically. And, show up at everything. … It’s not about what network you have, but how many networks you can get into.”

— Grace Rodriguez, CEO and executive director of Impact Hub Houston. On the "Equitable Growth Ecosystems for Entrepreneurs" panel, she was asked about how an entrepreneur might try to grow their network and mentorship.

"Houston is an incredibly industrial town. We have more Fortune 500 companies here than anywhere other than New York — most of them in the world of the dirty and dangerous. We don't have a lot of scooter companies."

— Gabriella Rowe, CEO of Station Houston. She was asked while on her panel, "Startup Funding: From Apprenticeships to Professions," about bootstrapping as a startup. Read more about this discussion here.

Jim Allison, immunotherapy researcher at MD Anderson and Nobel Prize recipient, is the subject of a new film that premiered at SXSW. Photo courtesy of MD Anderson Cancer Center

Film about Nobel Prize-winning Houston scientist premieres at SXSW

Now showing

For most of his career, James Allison has been a cancer research wildcatter fighting an oftentimes lonely battle for the advancement of immunotherapy. The medical community has historically been skeptical of the science, but nonetheless Allison dedicated his life to developing a better treatment to the disease that has claimed so many lives — including his mother's.

Last year, Allison, the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson, won the 2018 Nobel Prize in medicine, and Breakthrough, a film about Allison's progression from early researcher to Nobel Prize recipient, premiered on March 9 at the 2019 SXSW Interactive festival.

But despite the Nobel Prize and the new film both validating the science to the public, Allison says there's a lot more work to be done in immunotherapy. Allison, his colleague, Padmanee Sharma, and the filmmaker for Breakthrough, Bill Haney, hosted a discussion at SXSW about the future of immunotherapy.

"It's a time of considerable optimism — and we're just at the beginning," says Allison.

The film focuses on the man behind the science — a 70-year-old, harmonica-playing researcher from small-town Alice, Texas. It's both an ode to Allison's career and a thought-provoking take on all the work left to be done in the industry.

Immunotherapy is the process of targeting one's immune system's T-cells, infection-fighting white blood cells, to attack cancer cells. Sharma, a fellow MD Anderson oncology expert and clinician, says their work has received clinical approvals for treating Melanoma, kidney cancer, lung cancer, and bladder cancer. The scientists are now focused on expanding that treatment to other cancer types and building upon the established platform they've created, while also making sure nothing comes in the way of the facts of the science.

"It really requires that we dedicate ourselves to the basic science, understanding it and educating people about it, so we don't allow the facts and science get muddied by things that are political or nonfactual," Sharma says.

In a lot of ways, this is what Breakthrough has been able to do — communicate the facts on a platform where anyone can understand the science.

"We have a revolution on our hands, and thankfully we have people like Bill who can really tell the story well, because maybe as a scientist and a clinician, we're not always equally talented on telling the story to laypeople," Sharma says.

Moving forward, Allison says he's focused on finding out why the treatment fails in some instances, and he's determined to progress immunotherapy's success rate from the 20 to 40 percent rate he says he sees it at now to 100 percent.

"We've got all the basic tools, and we know what the main issues are," Allison says. "There's still a lot to do, but we need to be smart and do fact-based and mechanism-based combinations."

From pitch competitions to panels, here's how Houstonians will be representing at SXSW. Marie Ketring/via sxsw.org

10 can't-miss events at SXSW featuring Houston speakers

South by the Bayou

Plenty of Houstonians, SXSW badge in hand, will be headed to Austin to network, learn, and share the stage with the rest of the festivals attendees. While InnovationMap has highlighted a few of the faces to be on the lookout for this weekend, here's a roundup of 10 events that have a Houston speaker or participant.

3/8 — Featured Session: Opening Speaker, Brené Brown

SXSW is starting right out of the gate with a Houstonian. Brene Brown, a research professor at the University of Houston, will be the keynote address. Her thoughtful talk will focus on community and one's sense of belonging.

The SXSW keynote address will be at 11 am on Friday, March 8, at the Austin Convention Center. Learn more.

3/8 — Hysteria No More: Data, Doctors and Women’s Health

Gone are the days that medical professionals dismiss women's health concerns as "hysteria," but there's still room for improvement on the matter. Three ob/gyns will talk about new ways women are finding health care solutions outside the doctor's office.

Rashmi Kudesia, physician at CCRM Fertility Houston, is one of the panelists, which occurs on Friday, March 8, at the JW Marriott. Learn more.

3/8 — Equitable Growth Ecosystems for Entrepreneurs panel

The country has an equity problem — especially when it comes to startups and funding. Nationally, venture capital funds are not distributed in a way that represents the populations diversity, so how does the industry right the course?

Grace Rodriguez of Impact Hub Houston is among the panel that will discuss this at 3:30 pm on Friday, March 8, at the Hilton Austin Downtown. Learn more.

3/9 — Austinpreneur: The Texas Startup Manifesto

Texas is among the growing innovation ecosystems in the world, but there's plenty of untapped potential. This Capital Factory panel will focus on taking Texas to the next level.

Lawson Gow, founder and CEO of The Cannon, will be a panelist at the event, which begins at 11 am on Saturday, March 9, at the Hilton Austin Downtown. Learn more.

3/9 — Startup Funding: From Apprenticeships to Professions

Venture capitalism has changed tenfold since its start. Looking back on the history of early stage funding can help predict where it's going — from Silicon Valley to every corner of the world.

Station Houston CEO Gabriella Rowe is on the panel, which will take place at 12:30 pm on Saturday, March 9, at the Hilton Austin Downtown. Learn more.

3/9 — Making the Fight Against Cancer Even More Personal

No one loves discussing cancer, but there's a large group of scientists who have to daily and they develop new technologies and innovations to help discover a cure for the deadly affliction.

James Allison, researcher at the University of Texas MD Anderson Cancer Center and 2018 Nobel Prize recipient, will be on the panel discussing ways to innovate within cancer research. The program starts at 5 pm on Saturday, March 9, at the JW Marriott. Learn more.

3/10 — SXSW Pitch Presented by Cyndx Awards Ceremony

Two Houston startups are competing for an award in the 11th annual SXSW Pitch Event. Fluidity Technologies will be presenting as its drone controller, FT Aviator, in the Hyper-Connected Communities category on Saturday, March 9, at 5 pm, and Zibrio SmartScale, which is in the Health and Wearable category, will present on Sunday, March 10, at 5 pm.

The pitch awards will take place at 6:30 pm on Sunday, March 10, at the Hilton Austin Downtown. Learn more.

3/11 — Tech Diversity Report Card 2019

Is diversity and inclusion basically just a myth in technology? Is it something that's attainable at this point, and what can the industry do to make that happen? A group of panelists discuss based on their experience and observations.

Heidi Hoover, head of office at Houston-based Flanders Investment & Trade, will be a member of the panel, which occurs on Monday, March 11, at 5 pm, at Capital Factory. Learn more.

3/11 — Angel Investor Meetup

Calling all acting and aspiring investors — it's time to rally. Two Texas investors are gathering the troops to discuss trends and opportunities in the state's — and the world's — investment sector.

Samantha Lewis of Houston-based GOOSE Society of Texas will be one of the hosts of the meetup, which takes place on Monday, March 11, at 5 p.m, at the Fairmont Hotel. Learn more.

3/12 — AI & IoT Panel and Emerging Company Showcase

Houston-based Baker Botts and Global Corporate Venturing are setting the stage for emerging tech companies to shine. The event includes a panel, a showcase, and an evening of networking.

James McKell, of Chevron Technology Ventures, is representing Houston on the panel, which begins at 2 pm on Tuesday, March 12, at Hotel Van Zandt. Learn more.

Honorable mentions


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston

lilly lands

Leading pharmaceutical company Eli Lilly broke ground today, Sept. 21, on its $6.5 billion manufacturing site at Houston's Generation Park.

The 236-acre, state-of-the art factory is expected to come online in 2030 and will manufacture Foundayo, the company's first synthetic oral GLP-1 medication, as well as other advanced therapeutics.

"We are thrilled to break ground on our latest ‘medicines made in America’ site in the great state of Texas," David Ricks, Lilly chair and CEO, said in a prepared statement. "This $6.5 billion investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly’s latest products from Texas to people here at home and around the world.”

Houston was up against more than 300 locations in the U.S. for the factory, as part of Lilly’s $50 billion investment in domestic medicine production that has launched 10 manufacturing sites since 2020. Lilly first announced Houston had been selected for the site last September.

Photo via gov.texas.gov

As Abbott mentioned, the site is expected to create hundreds of jobs, and will hire engineers, scientists, operations personnel and lab technicians once up and running. It will create 4,000 construction jobs while being built.

In an effort to support workforce development, Lilly also announced a $12.5 million commitment to Houston's San Jacinto College in addition to a $2.5 million charitable donation to the San Jacinto College Foundation. The funding will go toward hands-on training, equipment and facilities to support future technicians, operators, maintenance professionals, and other manufacturing talent, according to Lilly. The charitable donation will fund scholarships for students.

"This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region,” Brenda Hellyer, chancellor of San Jacinto College, said in the release.

"When you invest in a place like Houston, you invest in its people first," Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added. "This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home."

Rendering courtesy Eli Lilly

Lilly previously said it chose Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, because of factors such as financial incentives, access to utilities and transportation and the region’s business-friendly environment. Generation Park is home to campuses for San Jacinto College and Lone Star College.

Since Lilly first announced plans for the site, another fellow pharma giant has made plans to move into Generation Park. Bristol Myers Squibb Co. announced last month that it would build a $2.3 billion factory in the district. The site is expected to manufacture small molecule, biologic and antibody-drug conjugates and will also come online around 2030. Read more here.

UH Health names leader of new digital health institute

new exec

Recently launched UH Health has named the first-ever executive director of its new Institute for Digital Healthcare Transformation at the University of Houston.

Beto López has been tapped to lead the new initiative that aims to help develop and commercialize health care technologies centered around university research.

Launched in August, the Institute for Digital Healthcare Transformation leans on experts from UH’s engineering, medicine, business, law and other departments and will connect with industry partners. It will initially focus on mobile health applications, sensors, wearables and artificial intelligence, according to UH.

“Most digital health initiatives and commercialization efforts start with the technology and hope adoption follows. But the translation gap isn't a science problem — it’s a scaffolding problem between researchers, the community and the market,” López said in a news release. “I've spent the past 10 years building that scaffolding in places that weren’t wired for it, and I'm looking forward to building it here at UH to help ensure new health care technologies reach the people and communities that can benefit from them most.”

López previously spent 10 years at San Francisco-based innovation consultancy company IDEO, where he led over 100 projects for Fortune 500 companies and public agencies. He co-founded and served as managing director of the Design Institute for Health at UT Austin’s Dell Medical School; and also co-founded a social venture studio/venture capital fund focused on health care innovation. He worked alongside Houston’s Legacy Community Health during the COVID-19 pandemic.

“Beto understands that breakthrough technology alone doesn't transform health care — it has to be designed around the needs of patients, providers and communities and have a clear path into practice,” Jonathan McCullers, vice president for health affairs at UH, added in the news release. “His experience spanning academic health care and venture capital equips him to bring together researchers, health care organizations, entrepreneurs and investors. This makes him uniquely suited to lead this institute and help turn the university's innovation into solutions that improve people's lives.”

The University of Houston launched UH Health, its new cross-disciplinary academic venture, in July. It aims to bring together the university's health-related education, research and community impact under one umbrella.

ExxonMobil gets approval for $5B Texas Gulf Coast carbon capture project

CCS Expansion

Spring-based ExxonMobil has won approval from the Texas Railroad Commission for a $5 billion carbon capture and storage project in East Texas.

Dominic Genetti, senior vice president of CCS at ExxonMobil, told The Financial Times, which broke the news, that the Railroad Commission’s action is a “major milestone” that lets the company keep expanding along the Gulf Coast. In a 2-1 vote, commissioners authorized a carbon sequestration permit for the project.

“The Railroad Commission clearly recognizes the important role carbon capture and storage can play in meeting growing global demand for lower-carbon products while supporting new jobs and economic growth,” Genetti said.

The U.S. Environmental Protection Agency (EPA) approved ExxonMobil’s Rose CCS project last year.

The project will enable the company to inject about 53 metric tons of industrial customers’ carbon emissions into three underground wells it drilled in the Beaumont-Port Arthur area. Over a 13-year period, ExxonMobil plans to inject about 4 million metric tons per year into the Fleming and Upper Frio rock formations, according to Carbon Herald.

ExxonMobil says it owns the world’s first and largest CCS system, comprising 1,300 miles of CO2 pipeline and secure storage sites. Seventy percent of the pipelines are along the Gulf Coast.

The company ramped up its CCS business in 2023 with the $4.9 billion purchase of Denbury, which owned about 1,000 miles of CO2 pipelines.

“Our expertise, combined with Denbury’s talent and CO2 pipeline network, expands our low-carbon leadership and best positions us to meet the decarbonization needs of industrial customers while also reducing emissions in our own operations,” ExxonMobil Chairman and CEO Darren Woods said when the deal closed.

In January, Genetti wrote in a post on ExxonMobil’s website that the company is committed to CCS “for the long haul.”

“CCS is not new technology, but it’s flown relatively under the radar compared with the attention that production of hydrocarbons commands,” he wrote. “Now, as the world becomes more aware of the need to reduce emissions, CCS finally has a brighter spotlight and a broader runway to scale up.”

The company also announced this week that it has begun CCS operations at a direct reduced iron facility in Convent, Louisiana. The project will capture, transport and store up to 800,000 metric tons of CO2 per year, according to the company.

---

This article first appeared on EnergyCapitalHTX.com.

View All Listings